By disrupting these interactions, galectin-3 inhibitors prevent the formation of oligomeric structures and lattice-like assemblies that are essential for activating pro-fibrotic signaling pathways, thereby halting fibrosis and reducing liver inflammation in MASLD patients [313]. Here, LGALS3 is linked to metabolic dysfunction-associated steatotic liver disease.